Tag: Alzheimer’s
Natural Environments May Cut Hospitalization for Patients With Neurodegenerative Diseases
Normalized difference vegetation index negatively associated with hospitalization for Alzheimer disease and related dementia, Parkinson disease
Congressional Report Slams FDA, Drugmaker Over Approval of Alzheimer Drug Aduhelm
Controversy over Aduhelm stretches back to its June 2021 approval by the U.S. Food and Drug Administration
PET Changes Similar for Alzheimer Disease, Down Syndrome
No difference seen in global PET amyloid burden between asymptomatic with Down syndrome, asymptomatic mutation carriers
Study Explores Impact of FDA Approval of Aducanumab on Trial Participation
Individuals who were independently aware of the FDA decision demonstrated reduced willingness to participate
Lecanemab Reduced Markers of Amyloid in Early Alzheimer Disease
Moderately less decline seen in cognition and function at 18 months with lecanemab versus placebo
Second Death in Trial of Experimental Alzheimer Drug Raising Concerns
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds
Telmisartan Linked to Reduced Risk for Alzheimer Disease in Black Patients
African American-specific beneficial effects of telmisartan identified in Mendelian randomization analysis
Phosphodiesterase-5 Inhibitors Not Tied to Alzheimer Disease Risk
No evidence seen for reduced risk for Alzheimer disease and related dementia across four separate analytic approaches
New Model Predicts Five-Year Alzheimer Dementia Risk
Model includes demographic information, brain imaging test results, and genetic biomarkers
AAO: Normal-Tension Glaucoma Tied to Higher Alzheimer Disease Risk
Authors say people with normal-tension glaucoma should be screened for Alzheimer disease
